MARKET WIREYahoo • 18h ago
EBay Leads Five Stocks Near Buy Points From Resilient SectorsEbay, Quest Diagnostics, Fastenal, Chubb trade in or around buy points after earnings. TG Therapeutics breaks out.
Why TGTX Stock advanced +1.19% Today — RQD Quant Desk Flash
$58.08 +1.19% NASDAQ • Public Delayed / 60s Snapshot
TG Therapeutics Inc. (TGTX) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (60/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+181.1% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
ROARABLE D • SELL / AVOID
Cap $8.89B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+0.9% Base Target
WHALE OPTIONS TUG-OF-WAR:61% Call Buyers ($2.7M)
39% PutsMax Pain: $57.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TGTX Stock advanced +1.19% Today — RQD Quant Desk Flash
TG Therapeutics Inc. (TGTX) advanced +1.19% to $58.08 as options desks priced 61% call premium vs. 39% put protection around the $57 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+181.1% (NI vs OCF)) as receivables rose.
- ▸Technical Tape: Trading at 89% of its 52-week range ($26.76 – $61.76) with RSI-14 at 69.7 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $2.7M in bullish call flow vs. $1.8M in put flow (Put/Call 0.65x, implied earnings swing ±6.5%).
- ▸Primary SEC / Cross-Feed Trigger: TGTX Accounting Gap: Net Income (+220%) Outpaced OCF (+38.9%) With +-44.6% Working-Capital Build
Live TGTX Headlines & Catalysts
MARKET WIREYahoo • 1d ago
TG Therapeutics Is Up 98%, But The Story Isn't FinishedOne concrete shift for TG Therapeutics this year was the push to simplify and broaden BRIUMVI use, from single 600 mg Day 1 infusions in relapsing multiple sclerosis to new trials in conditions like myasthenia gravis and
MARKET WIREYahoo • 1d ago
TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout BuzzInvestors are now focused on the company’s projected third-quarter 2026 results, estimated for Monday, November 2.
CATALYSTYahoo • 1d ago
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthGilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
CATALYSTYahoo • 1d ago
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceInsmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
CATALYSTYahoo • 1d ago
Edwards' Q3 Earnings on the Horizon: What's in the Cards?EW heads into Q3 with TAVR momentum, expanding mitral and tricuspid therapies and surgical heart growth. Can it beat earnings estimates?
CATALYSTYahoo • 2d ago
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedIncyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
RISK WATCHYahoo • 2d ago
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesViking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
MARKET WIREYahoo • 2d ago
Amarin's Q3 Earnings Beat Estimates, Revenues Miss MarkAMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
CATALYSTYahoo • 2d ago
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive GrowthGRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TGTX)
- ✓Live walkthrough of TGTX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
TGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +81.11%▲ RESISTANCE BREAKOUT
2026-10-30O $58.15H $61.76L $58.00C $61.18VOL 2.85M
RES: $59.92SUP: $52.40SMA50: $55.33SMA200: $43.81
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
13.4%/yr Implied 5Y Growth
vs. +87.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TGTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TGTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TGTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
TGTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TGTX stock moving today?
Why TGTX Stock advanced +1.19% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+181.1% (NI vs OCF)) as receivables rose.